84-3649-22　［取扱停止］VEGFR-2 (Vascular Endothelial Growth Factor Receptor 2, VEGFR-2, FLK-1, KDR) (VEGFR2, VEGFR 2, Protein-tyrosine kinase receptor flk-1, Fetal liver kinase 1, Kinase NYK, FLK1, KDR, Kinase insert domain receptor, KRD1, Ly73, Protein tyrosine kinase receptor FLK1, Vascular endothelial growth factor receptor 2) (AP) 100ul　V2110-18F-AP

特徴

• Vascular endothelial growth factor receptor-2 (VEGFR-2), also known as fetal liver kinase 1 (FLK-1) in mouse and KDR in human, is a transmembrane tyrosine kinase that plays an important role in the development of the vascular system and the vascularization of a wide variety of tumors.
• Binding of VEGF to VEGFR-2 leads to tyrosine phosphorylation of the dimerized receptor and subsequent phosphorylation of SH2-containing intracellular signaling proteins, including phospholipase C, Src family tyrosine kinase and phosphatidylinositol 3-kinase (PI3K) adaptor molecules, SHC, NCK, and Ras GTPase-activating protein.
• VEGFR-2 is expressed in cultured human umbilical vein endothelial cells (HUVEC), Hela cells, WM 35 melanoma cells, WM 9 melanoma cells, as well as mouse NIH3T3, and Balb/c 3T3 cells.
• In a single study of 115 paraffin-embedded cancer specimens analyzed by immunohistochemistry, VEGFR-2 expression was observed in bladder tumors, breast cancer, intestinal cancer and lung cancer, suggesting a direct role for VEGF as an autocrine growth factor in a variety of human cancers.
• Applications:Suitable for use in ELISA and Western Blot.
• Other applications not tested.
• Recommended Dilution:ELISA: 0.1-1ug/mlWestern Blot: 1–5ug/ml Optimal dilutions to be determined by the researcher.
• Storage and Stability:Store product at 4°C.
• DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid.
• Dilute required amount only prior to immediate use.
• Further dilutions can be made in assay buffer.
• For maximum recovery of product, centrifuge the original vial prior to removing the cap.
• Note: Applications are based on unconjugated antibody.